Mantle cell lymphoma

From Ganfyd

Jump to: navigation, search

Mantle cell lymphoma has a poor long-term prognosis which has improved in the last few decades with now quoted median time to treatment failure of just over 9 years. Long term survival is still problematical.

Most are characterised by the t(11;14) translocation that results in a fusion protein between IgH and cyclin D1. Other cyclin D partners have been described.




Chemotherapy is the standard treatment with high-dose cytarabine and immunochemotherapy before autologous stem-cell transplantation being the current standard of treatment in those less than 65 years[1].